loading
Precedente Chiudi:
$284.98
Aprire:
$284.44
Volume 24 ore:
65,679
Relative Volume:
0.21
Capitalizzazione di mercato:
$6.27B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-11.18
EPS:
-25.12
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
-0.69%
1M Prestazione:
+4.94%
6M Prestazione:
-10.01%
1 anno Prestazione:
+0.26%
Intervallo 1D:
Value
$278.04
$284.99
Intervallo di 1 settimana:
Value
$276.67
$290.00
Portata 52W:
Value
$200.63
$377.46

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Name
Nome
Madrigal Pharmaceuticals Inc
Name
Telefono
404-380-9263
Name
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Name
Dipendente
528
Name
Cinguettio
@MadrigalPharma
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
MDGL's Discussions on Twitter

Confronta MDGL con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
MDGL
Madrigal Pharmaceuticals Inc
280.77 6.27B 0 -518.67M -438.32M -25.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.98 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
519.67 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.81 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
563.56 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
267.22 28.51B 3.81B -644.79M -669.77M -6.24

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-28 Aggiornamento B. Riley Securities Neutral → Buy
2025-02-27 Reiterato H.C. Wainwright Buy
2024-06-28 Iniziato Cantor Fitzgerald Neutral
2024-06-11 Iniziato Wolfe Research Outperform
2024-04-22 Iniziato BofA Securities Underperform
2024-03-15 Aggiornamento B. Riley Securities Sell → Neutral
2024-03-06 Iniziato Citigroup Buy
2024-02-26 Downgrade B. Riley Securities Neutral → Sell
2022-12-20 Reiterato Oppenheimer Outperform
2022-12-19 Reiterato H.C. Wainwright Buy
2022-12-19 Reiterato Piper Sandler Overweight
2022-12-19 Aggiornamento Raymond James Underperform → Mkt Perform
2022-07-08 Downgrade B. Riley Securities Buy → Neutral
2021-10-07 Iniziato Jefferies Buy
2021-08-06 Aggiornamento BMO Capital Markets Market Perform → Outperform
2021-05-20 Ripresa Goldman Buy
2020-11-24 Ripresa Evercore ISI Outperform
2020-11-06 Reiterato H.C. Wainwright Buy
2020-07-31 Iniziato Piper Sandler Overweight
2020-06-05 Iniziato BMO Capital Markets Market Perform
2020-05-05 Iniziato Chardan Capital Markets Buy
2020-01-30 Iniziato Canaccord Genuity Buy
2020-01-09 Aggiornamento UBS Neutral → Buy
2019-11-07 Reiterato H.C. Wainwright Buy
2019-06-25 Iniziato Stifel Hold
2019-06-10 Aggiornamento B. Riley FBR Neutral → Buy
2019-02-28 Reiterato H.C. Wainwright Buy
2019-02-22 Iniziato SVB Leerink Outperform
2019-01-23 Iniziato UBS Neutral
2018-12-14 Iniziato Wolfe Research Outperform
2018-12-12 Iniziato B. Riley FBR Neutral
2018-11-19 Downgrade Raymond James Mkt Perform → Underperform
2018-11-16 Aggiornamento Evercore ISI In-line → Outperform
2018-09-04 Iniziato Citigroup Buy
2018-08-06 Downgrade Goldman Buy → Neutral
2018-06-28 Iniziato Raymond James Mkt Perform
Mostra tutto

Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie

pulisher
Jun 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 17, 2025
pulisher
Jun 16, 2025

EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others - insights.citeline.com

Jun 16, 2025
pulisher
Jun 15, 2025

(MDGL) Investment Analysis - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 13, 2025

Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference - MSN

Jun 13, 2025
pulisher
Jun 11, 2025

Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Predicts MDGL FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World

Jun 09, 2025
pulisher
Jun 06, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Jun 06, 2025
pulisher
Jun 03, 2025

(MDGL) On The My Stocks Page - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 02, 2025

Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewswire

Jun 02, 2025
pulisher
May 29, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Ameriprise Financial Inc. - Defense World

May 29, 2025
pulisher
May 28, 2025

Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com

May 28, 2025
pulisher
May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com

May 26, 2025
pulisher
May 26, 2025

Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK

May 26, 2025
pulisher
May 25, 2025

Cetera Investment Advisers Has $889,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World

May 25, 2025
pulisher
May 23, 2025

When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com

May 23, 2025
pulisher
May 17, 2025

In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha

May 17, 2025
pulisher
May 16, 2025

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma - insights.citeline.com

May 16, 2025
pulisher
May 15, 2025

Will Other Major MASH Deals Follow GSK/Boston Pharma? - insights.citeline.com

May 15, 2025
pulisher
May 13, 2025

2 Monster Stocks in the Making to Buy Now and Hold for 10 Years - AOL.com

May 13, 2025
pulisher
May 13, 2025

Transcript : Madrigal Pharmaceuticals, Inc.Special Call - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Where are the Opportunities in (MDGL) - news.stocktradersdaily.com

May 13, 2025
pulisher
May 13, 2025

Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN

May 13, 2025
pulisher
May 11, 2025

Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN

May 11, 2025
pulisher
May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus

May 11, 2025
pulisher
May 11, 2025

MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus

May 11, 2025
pulisher
May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times

May 10, 2025
pulisher
May 10, 2025

Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com

May 10, 2025
pulisher
May 10, 2025

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.

May 10, 2025
pulisher
May 08, 2025

Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey

May 08, 2025
pulisher
May 07, 2025

Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey

May 07, 2025
pulisher
May 06, 2025

Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra (NASDAQ:MDGL) - Seeking Alpha

May 06, 2025
pulisher
May 06, 2025

Billionaire John Paulson’s 10 Stocks with Huge Upside Potential - Insider Monkey

May 06, 2025
pulisher
May 05, 2025

What is B. Riley’s Estimate for MDGL FY2028 Earnings? - Defense World

May 05, 2025
pulisher
May 04, 2025

Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st

May 04, 2025
pulisher
May 03, 2025

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey

May 03, 2025
pulisher
May 03, 2025

Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus

May 03, 2025
pulisher
May 02, 2025

(MDGL) Trading Signals - news.stocktradersdaily.com

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Stron - GuruFocus

May 02, 2025
pulisher
May 02, 2025

UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus

May 02, 2025
pulisher
May 02, 2025

UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN

May 02, 2025

Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Madrigal Pharmaceuticals Inc Azioni (MDGL) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
CRAVES FRED B
Director
Mar 13 '25
Option Exercise
65.06
7,742
503,695
357,818
CRAVES FRED B
Director
Mar 12 '25
Sale
331.84
7,728
2,564,426
350,076
CRAVES FRED B
Director
Mar 13 '25
Sale
325.25
7,742
2,518,053
350,076
$20.50
price down icon 1.14%
$35.88
price down icon 0.69%
$21.02
price up icon 0.67%
$104.62
price down icon 1.31%
$102.67
price down icon 2.16%
biotechnology ONC
$267.54
price up icon 0.36%
Capitalizzazione:     |  Volume (24 ore):